Integrity Coronary Stent System    

Log In
 
 

Forgot Your Password?
 


Not a member? Click here!

Low-Molecular Weight Heparins in STEMI: The CREATE Trial
Time to Treatment (and Transport) Issues: Selection of Reperfusion Modality, and Primary Angioplasty with No On-Site Surgery
Fondaparinux in ACS
Low-Molecular Weight Heparins in ACS: New Insights from SYNERGY and STEEPLE
Status of Primary PCI in the US: Lessons From NRMI (Comparison With Thrombolysis, Impact of Time, Magnitude, Reasons for Delays, and More)






 

 

The Heat is on Bivalirudin

The HEAT-PPCI trial, a single-center randomized trial of 1829 patients undergoing PPCI, compared the use of unfractionated heparin with bivalirudin with bailout GP IIb/IIIa inhibitors. The study has concluded that the use of heparin was associated with lower MACE and stent thrombosis with no difference in the rates of bleeding.

For more, click here

 

 

 

BRAVE-4 Favors an Old Fashioned Approach

The BRAVE-4 trial, comparing a strategy of bivalirudin and prasugral with unfractionated heparin and clopidogrel in patients undergoing PPCI, has been terminated early due to slow recruitment. Analysis of the 548 enrolled patients has shown no differences in the net clinical outcome at 30 days.

For more, click here

 

 

 

Accuracy of iFR Need Resolving

The diagnostic accuracy of iFR and Pd/Pa, as compared with invasive FFR, remains unclear. Analysis of 1593 lesions has shown that that iFR and Pd/Pa had ≥90% accuracy in predicting a positive or negative FFR in 64.9% and 48.3% of lesions.

For more, click here

 

 

 

The Enigma of Vitamin D Supplementation

There are increasing calls for widespread vitamin D supplementation given the contribution of this vitamin in a variety of pathological disorders. A meta-analysis of studies examining the impact of vitamin D supplementation has found no beneficial effects upon MI, ischemic heart disease, stroke, cerebrovascular disease, cancer, or total fracture by a actor of 15% or more.

For more, click here

 

<
||
>















CRT2013
Untitled Document
 
2013 ACS: Year in Review
- Robert P. Giugliano, MD
CoreValve US Pivotal Trials
- Michael J. Reardon, MD
IN.PACT SFA - Randomized Trial of IN.PACT Admiral DCB vs. PTA for the Treatment of Atherosclerotic Lesions in the SFA and/or PPA: 1-year Primary Outcomes
- Gunnar Tepe, MD
Dual Antiplatelet Therapy (DAPT) Duration Dilemma: Recent Trials And Guidelines For Clinical Practice
- Dean J. Kereiakes, MD
Coronary microvascular dysfunction
- Filippo Crea, MD




Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD



Josep Rodés-Cabeau, MDAntithrombotic treatment in TAVI
- Josep Rodés-Cabeau, MD
 Click here to visit the WEBEX archives


Proposal for a Functional Classification System of Heart Failure in Patients With End-Stage Renal Disease. Proceedings of the Acute Dialysis Quality Initiative (ADQI) XI Workgroup.
L Chawla, et al.
JACC 2014; 63:1246-1252
Multicenter Core Laboratory Comparison of the Instantaneous Wave-Free Ratio and Resting Pd/Pa With Fractional Flow Reserve. The RESOLVE Study.
A Jeremias, et al.
JACC 2014; 63:1253-1261
Yield of Downstream Tests After Exercise Treadmill Testing. A Prospective Cohort Study.
M Christman, et al.
JACC 2014; 63:1264-1274
Risk for Myocardial Infarction and Stroke After Community-Acquired Bacteremia. A 20-Year Population-Based Cohort Study.
M Dalager-Pdersen, et al.
Circ 2014; 129:1387-1396
National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation.
J Dlott, et al.
Circ 2014; 129:1407-1414
Postprocedural Aortic Regurgitation in Balloon-Expandable and Self-Expandable Transcatheter Aortic Valve Replacement Procedures. Analysis of Predictors and Impact on Long-Term Mortality: Insights From the FRANCE2 Registry.
E Van Belle, et al.
Circ 2014; 129:1415-1427
The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis.
M Bolland, et al.
The Lancet Diabetes and Endocrinology 2014; 2:307-320
A gender-sensitised weight loss and healthy living programme for overweight and obese men delivered by Scottish Premier League football clubs (FFIT): a pragmatic randomised controlled trial.
K Hunt, et al.
The Lancet 2014; 383:1211-1221
Meta-Analysis of Outcomes After Intravascular Ultrasound–Guided Versus Angiography-Guided Drug-Eluting Stent Implantation in 26,503 Patients Enrolled in Three Randomized Trials and 14 Observational Studies.
J Ahn, et al.
AJC 2014; 113:1338-1347




Poll Archives

CRYSTAL AF: Long-Term Follow-Up Results
Rod S. Passman, MD, et al.
A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed High-Risk for Surgery
David H. Adams, MD
Results of the SYMPLICITY HTN 3 Trial
Deepak L. Bhatt, MD, MPH, et al.
Four-Year Outcomes Following Resolute Zotarolimus-Eluting Stent Implantation: RESOLUTE US Study
David Lee, MD, et al.
Does IVUS Have Any Role in Evaluating Intermediate Lesions?
Ron Waksman, MD
The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension
Michael Böhm, MD
HEAT PPCI Study
Adeel Shahzad, MD, et al.
(GIPS)-III trial
Chris P.H. Lexis, MD, et al.
Results of the MSC-HF Trial
Anders Bruun Mathiasen, MD
The NOBORI Biolimus-Eluting versus XIENCE/PROMUS Everolimus-eluting Stent Trial (NEXT)
Masahiro Natsuaki, MD
A Subanalysis of the OPTIMIZE Clinical Trial
Fausto Feres, MD, et al.
OPTIMIZE Clinical Trial
Ricardo A. Costa, MD, et al.
POISE-2 Trial - Aspirin in Patients Undergoing Noncardiac Surgery
PJ Devereaux, MD
ZEUS Trial
M. Valgimigli, MD, PhD
STAMPEDE Trial
Philip R Schauer, MD, PhD
SIRS Trial
Population Health Research Institute
Patterns of Left Ventricular Remodeling in Patients with Severe Aortic Stenosis in The PARTNER Trial
Sammy Elmariah, MD
Outcomes of Inoperable Patients Undergoing Transapical and Transaortic Transcatheter Aortic Valve Replacement
Mathew Williams, MD
A Randomized Comparison of Vascular Complications after TAVR Comparing the SAPIEN vs. The Lower-Profile SAPIEN XT System in Inoperable Aortic Stenosis Patients
Augusto D. Pichard, MD
30 Day Outcomes from The PARTNER II Trial for Transapical and Transfemoral 29mm TAVR in Inoperable Patients with the Edwards SAPIEN XT
Vasilis Babaliaros, MD
Costs of Periprocedural Complications in Patients Treated with Transcatheter Aortic Valve Replacement
Suzanne V. Arnold, MD
Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses
John Webb, MD, et al.

Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
BIOFLOW-II Trial
Stephan Windecker, MD, et al.

Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD
The RESOLUTE Program: today and tomorrow
Sigmund Silber, MD, PhD
RESOLUTE International Trial
F-J. Neumann, MD, et al.
Primary Results Following Percutaneous Coronary Intervention with the 38mm Resolute Zotarolimus-eluting Stent
Shirish Hiremath, MD, et al.
Two Year Outcomes Following Implantation of the Resolute Zotarolimus-eluting Stent in Small (less or equal to 2.5 mm) Vessels
Ronald Caputo, MD


ACS & AMI
Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2013 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login


Copyright © 2014, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb